scholarly journals Clinical Efficacy And Safety Of Licensed Drugs And Potential New Therapies For Non-Metastatic Castration-Resistant Prostate Cancer: A Systematic Literature Review

2017 ◽  
Vol 20 (9) ◽  
pp. A458
Author(s):  
S Naidoo ◽  
I Smith ◽  
M Casamayor
Keyword(s):  
Prostate Cancer ◽  
Literature Review ◽  
Clinical Efficacy ◽  
Systematic Literature Review ◽  
Efficacy And Safety ◽  
Castration Resistant Prostate Cancer ◽  
New Therapies ◽  
Castration Resistant

scholarly journals Initial evaluation of the clinical efficacy and safety of enzalutamide in castration-resistant prostate cancer

2015 ◽  
Vol 26 ◽  
pp. vii145
Author(s):  
Noriyoshi Miura ◽  
Toshio Kakuta ◽  
Terutaka Noda ◽  
Seiji Asai ◽  
Tetsuya Fukumoto ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Efficacy ◽  
Initial Evaluation ◽  
Efficacy And Safety ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

New Therapies for Castration-Resistant Prostate Cancer: Efficacy and Safety

2011 ◽  
Vol 60 (2) ◽  
pp. 279-290 ◽  
Author(s):  
Himisha Beltran ◽  
Tomasz M. Beer ◽  
Michael A. Carducci ◽  
Johann de Bono ◽  
Martin Gleave ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Efficacy And Safety ◽  
Castration Resistant Prostate Cancer ◽  
New Therapies ◽  
Castration Resistant

Survival outcomes of pre-metastatic castration-resistant prostate cancer and the burden of developing metastasis: A systematic literature review.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 293-293 ◽  
Author(s):  
Neal D. Shore ◽  
Gershwinder Rai ◽  
Karim Fizazi ◽  
Laura Wilson ◽  
Lin Zhan
Keyword(s):  
Prostate Cancer ◽  
Bone Metastasis ◽  
Literature Review ◽  
Systematic Literature Review ◽  
Survival Outcomes ◽  
Castration Resistant Prostate Cancer ◽  
Economic Implications ◽  
Free Survival ◽  
Physician Visits ◽  
Castration Resistant

293 Background: Surgical or medical castration is an important component of prostate cancer treatment. However, resistance develops in almost all men and poor prognosis has been established once the disease metastasizes. A systematic literature review (SLR) was conducted to explore the treatment options and survival outcomes associated with non-metastatic castration-resistant prostate cancer (CRPC) and to understand the humanistic and economic impact of developing metastasis. Methods: The SLR was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement guidelines and guidance from the National Institute of Health and Care Excellence, Centre for Reviews and Dissemination and Institute for Quality and Efficiency in Healthcare. The search designed to identify clinical and humanistic evidence from all countries and epidemiology, guidelines and economic evidence in Brazil, China, France, Germany, Japan, UK, and US. Results: Median overall survival for non-metastatic CRPC patients ranged from 44 to 74 months; median progression-free survival from 9 to 22 months; and median metastasis-free survival from 16 to 53 months. The most common form of metastasis was bone metastasis, which was associated with an increased risk of skeletal-related events (SREs). Quality-of-life was widely reported to decrease upon metastasis, driven by increased pain and SREs. Higher healthcare costs associated with metastatic CRPC were attributable to physician visits and treating bone-metastasis-related complications. Conclusions: Currently, there is a lack of approved therapies specifically for non-metastatic CRPC patients, who will invariably develop metastases with associated adverse clinical and economic implications. Delaying the onset of metastasis is an unmet clinical need for improved patient outcomes and couldl also lead to economic benefits for healthcare delivery systems.

Efficacy and safety of 4-weekly docetaxel for castration-resistant prostate cancer

2021 ◽  
pp. 1-15
Author(s):  
Takuya Yamashita ◽  
Masaki Shiota ◽  
Asako Machidori ◽  
Satoshi Kobayashi ◽  
Takashi Matsumoto ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Efficacy And Safety ◽  
Castration Resistant Prostate Cancer ◽  
Weekly Docetaxel ◽  
Castration Resistant

scholarly journals Resolution of the Expert Council on the New Approach to Drug Therapy for Non-Metastatic Castration-Resistant Prostate Cancer

2021 ◽  
Vol 59 (1) ◽  
pp. 8-11
Author(s):  
Dilyara Kaidarova ◽  
Oxana Shatkovskaya ◽  
Zaure Dushimova ◽  
Bakytzhan Ongarbayev
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Treatment Efficacy ◽  
Doubling Time ◽  
Distant Metastases ◽  
Diagnostic Methods ◽  
Efficacy And Safety ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Psa Doubling Time

Relevance: Prostate cancer (PC) is one of the most common malignant neoplasms in the male population. The widespread introduction of modern diagnostic methods and the determination of prostate-specific antigen (PSA) levels have increased the number of detected cases of localized and locally advanced PC forms. However, in some patients treated with radical methods and long-term androgen deprivation therapy (ADT), the disease continues to progress in the form of an increase in PSA levels with castration testosterone values and with no distant metastases. Such a course of the disease is referred to as non-metastatic castration-resistant prostate cancer (nmCRPC). Purpose: The article reports the results of a meeting of the Expert Council arranged by the Kazakh Research Institute of Oncology and Radiology on December 25, 2020, on non-metastatic castration-resistant prostate cancer diagnostics and treatment. Results: Large clinical studies highlight the critical importance of controlling the PSA doubling time as the main prognostic factor for an unfavorable outcome to increase patient survival and prevent the development of distant metastases. Based on the results of large randomized studies, experts recommended using new-generation androgen receptor antagonists in combination with ongoing ADT to improve the clinical outcomes in nmCRPC patients at high risk of metastatic progression. The Expert Council was presented with the data of a registration clinical study on darolutamide efficacy and safety. The advantages of introducing this drug into clinical practice to expand the choice of therapeutic options were identified. Personalized adjustment of a treatment regimen will increase the treatment efficacy and ensure higher survival in this category of patients. Conclusion: Increasing survival as the main objective in treating nmCRPC patients requires improved diagnostics through regular controlling of testosterone and PSA levels, calculation of PSA doubling time, and the use of radiological diagnostic methods to rule out distant metastases. The choice of therapy in patients at high risk of metastasis shall consider the patient’s status and the treatment efficacy and safety balance.

Sign in / Sign up

Export Citation Format

Share Document